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INTRODUCTION 
 
     In 1940, Reid and Brace first described hemodynamic response to 
laryngoscopy and intubation. 
        Laryngoscopy and endotracheal intubation are mandatory for most 
patients undergoing general anaesthesia, which is invariably associated 
with certain cardiovascular changes such as tachycardia or bradycardia, 
rise in blood pressure and a wide variety of cardiac arrhythmias. These 
effects are deleterious in susceptible individuals culminating in 
perioperative myocardial ischemia, acute heart failure and 
cerebrovascular accidents.  The hemodynamic response to laryngoscopy 
and endo tracheal intubation has been recognized since 1951. The 
induction of anaesthesia, laryngoscopy and intubation and surgical 
stimulation often evoke cardiovascular response characterized by 
alterations in systemic arterial pressure, pulse rate and cardiac rhythm. 
The response following laryngoscopy and intubation peaks at 1.2 minute 
and returns to normal within 5 – 10 minutes. 
    Though these sympathoadrenal response are probably of little 
consequence in healthy individuals, it is hazardous to those patients with 
hypertension, coronary heart disease, intra cranial pathology and hyper 
reactive airways. In such cases, reflex circulatory response such as 
increase in heart rate, systemic arterial blood pressure and disturbances in 
cardiac rhythm needs to be suppressed. Prof. King et al (1951) 
documented myocardial ischemic changes due to reflex sympthoadrenal 
response immediately following laryngoscopy and intubation with a mean 
rise in systemic pressure of 40 mm Hg even in normotensive individuals. 
    Various systemic as well as topical agents were used to reduce 
these untoward hemodynamic responses due to laryngoscopy and 
intubation. Those technique which require prior laryngoscopy to the local 
anaesthetic solution are likely to be of limited value. The common 
strategies adopted are narcotics, vasodilators, beta blockers, calcium 
channel blockers, lidocaine other sympatholytics.  
             IV Esmolol due to its ultra short action seem to be ideal to control 
intense but brief sympathetic stimulation following endotracheal 
intubation. 
             Hence, the above study was done in the Department of 
Anaesthesiology, Chengalpattu Medical College, Chengalpattu.  
 
AIM 
 
The hemodynamic response during laryngoscopy and intubation 
should be abolished to balance the myocardial oxygen supply and 
demand for the safe conduct of anaesthesia. This study was done to 
compare the varying doses of IV Esmolol in attenuating the 
hemodynamic stress response to laryngoscopy and endo tracheal 
intubation. 
 
 
 
 
 
 
 
 
 
 
PATHOPHYSIOLOGY OF HEMODYNAMIC RESPONSES TO 
LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION 
 
Intubation of trachea alters the respiratory and cardiovascular 
physiology by both reflex response and by physical presence of endo 
tracheal tube. Although reflex responses are generally of short duration 
and of little consequence in majority of patients, they may produce 
profound disturbance in patients with underlying abnormalities such as 
hypertension, coronary heart disease, reactive airways, intra cranial 
pathology.  
CARDIOVASCULAR RESPONSES: 
         The cardiovascular responses to laryngoscopy and intubation are 
bradycardia, tachycardia, hypertension, and they are mediated by both the 
sympathetic and parasympathetic nervous system. Bradycardia is often 
seen in infants and small children during laryngoscopy and intubation. 
Although only rarely seen in adults this reflex is mediated by increase in 
vagal tone at sinoatrial node and is virtually a monosynaptic response to a 
noxious stimuli in airway.   
  The more common response to endotracheal intubation is 
hypertension and tachycardia mediated by sympathetic efferent via the 
cardioaccelerator nerves and sympathetic chain ganglia. The polysynaptic 
nature of pathways from IX and X nerve afferents to sympathetic nervous 
system.via the brain stem and spinal cord in a diffuse autonomic response 
which includes widespread release of norepinephrine from adrenal nerve 
terminals and adrenal medulla. 
      Some of the hypertensive response to endotracheal intubation also 
results from activation of renin angiotensin system, with release of renin 
from the renal juxta glomerular apparatus and end organ innervated by 
beta adrenergic nerve terminals. 
       The effects of endotracheal intubation on the pulmonary 
vasculature are less well understood then the responses elicited in the 
systemic circulation. They are often coupled with the changes in airway 
reactivity associated with intubation. They are i) glottis closure reflex       
( laryngospasm due to brisk motor response ), ii) decrease in dead space, 
iii) increase in airway resistance, iv ) bronchospasm ( a reflex response to 
iintubation ), v) removal of glottic barrier and may reduce lung volume, 
vi) cough efficiency is reduced. 
 
METHODS TO ATTENUATE CIRCULATORY RESPONSE 
DURING LARYNGOSCOPY AND INTUBATION 
 
                 The balance between myocardial oxygen supply and demand 
must be preserved to minimize the risk of peri operative ischemia and 
infarction. 
                 Factors affecting myocardial oxygen demand and supply. 
Demand 
           Basal requirement 
           Heart rate 
           Wall tension – preload, afterload 
           Contractility 
Supply  
          Heart rate – depends on diastolic time, hence decreases in heart 
rate, more diastolic time, more the oxygen supply to myocardium. 
  Coronary Perfusion Pressure – depends on Aortic diastolic pressure and 
ventricular end diastolic pressure and increase with high aortic diastolic 
pressure and low ventricular end diastolic  pressure. 
 
          Arterial oxygen content – depends on arterial oxygen partial 
pressure and haemoglobin concentration.  
          Coronary vessel diameter. 
Numbers of methods were used to attenuate cardiovascular 
response due to laryngoscopy and intubation. 
1.   Deepening of General Anaesthesia : 
Inhalational agents ‘MAC’ (i.e.) the dose of volatile agent required 
to blunt the cardiovascular responses to laryngoscopy and intubation. 
This deep level is achieved by inhalational agents result in profound 
cardiovascular depression prior to laryngoscopy and intubation. Various 
agents used are Halothane, Isoflurane, Sevoflurane.  
2. Lidocaine : 
¾ Lidocaine gargle for oropharyngeal anaesthesia. 
¾ Aerosol for intra tracheal anaesthesia 
¾ Topical spray for vocal cords 
¾ Regional nerve blocks – Superior Laryngeal nerve, 
Glossopharyngeal nerve 
¾ Intra venous bolus of systemic anaesthesia 
¾ Topical anaesthesia of upper airway has proven to be less effective 
than systemic administration of lidocaine. 
Mechanism of action  
By increasing the depth of General Anaesthesia 
Potentiation of effects of Nitrous Oxide and reduction of MAC of    
Halothane by 10 – 28 % 
Direct cardiac depressant 
Peripheral vasodilation 
Antiarrhythmic properties 
Suppression of cough reflex 
3. Vasodilators  
Hydralazine, Sodium nitro prusside, Nitroglycerine 
4. Narcotics  
Fentanyl, Alfentanil, Sufentanil, Pethidine, Morphine. 
Fentanyl is most common used narcotic agent. It is a potent 
analgesic, has short duration of action does not increase intra cranial 
tension, and has minimal circulatory changes. 
Mechanism of action 
Suppression of Nociceptive stimulation caused by Intubation 
Centrally mediated decrease in sympathetic tone 
Activation of vagal tone. 
5. Adrenergic blockers  
Long acting – Metoprolol, Phentolamine, Proponalol, Labetalol 
Short acting – Esmolol.  
Most commonly used agent because of its ultrashort action. It 
decreases heart rate, ejection fraction, and cardiac index but maintains 
coronary perfusion pressure. 
6. Calcium Channel Blockers  
Nifedipine, Nicardipine,- has got superior action 
Verapamil, Diltiazem  
7. Alpha 2 agonist-Clonidine 
8. Midazolam – Sedative & Anxiolytic 
9. Magesium Sulphate - Sedative & Anxiolytic 
 
  
NERVE SUPPLY OF LARYNX 
 
Nerve supply of the larynx is from the Vagus nerve by way of its 
superior laryngeal nerve and recurrent laryngeal branches. The Superior 
Laryngeal nerve arises from the inferior ganglion of Vagus and receives 
branch from the Superior cervical sympathetic ganglion. The external 
branch provides motor supply to the cricothyroid muscle while the 
internal branch pierces the thyrohyoid membrane and divides into two 
main sensory and secretomotor branches. The upper branch supplies the 
mucous membrane of lower part of pharynx, epiglottis, vallecula and 
vestibule of larynx. The lower branch supplies the aryepiglottic fold and 
mucous membrane down to the level of vocal folds. 
The internal branch of superior laryngeal nerve supplies the 
supraglottic area. 
  The Recurrent laryngeal nerve ascends to the larynx in the groove 
between the oesophagus and trachea and divides into motor and sensory 
branches. 
The motor branch has fibres derived from the cranial root of the 
accessory nerve which supplies all the intrinsic muscles of larynx except 
the cricothyroid. 
The sensory branch supplies the laryngeal mucous membrane 
below the level of vocal folds. 
  
PHARMACOLOGY OF ESMOLOL 
Esmolol hydrochloride is a beta1-selective (cardioselective) 
adrenergic receptor blocking agent with a very short duration of action 
(elimination half-life is approximately 9 minutes). The chemical name for 
Esmolol hydrochloride is (±)-Methyl p-[2-hydroxy-3-(isopropylamino) 
propoxy] hydrocinnamate hydrochloride and it has the following 
structure: 
 
Esmolol hydrochloride has the molecular formula C16H26NO4CI 
and a molecular weight of 331.8. It has one asymmetric center and exists 
as an enantiomeric pair. 
 
Esmolol HCl Injection is a clear, colourless to light yellow, sterile, 
nonpyrogenic solution. 100 mg, 10 mL Single Dose Vial - Each mL 
contains 10 mg Esmolol Hydrochloride and Water for Injection. 
 
Esmolol - Clinical Pharmacology 1 ,2 
Esmolol hydrochloride is a beta1-selective (cardioselective) 
adrenergic receptor blocking agent with rapid onset, a very short duration 
of action, and no significant intrinsic sympathomimetic or membrane 
stabilizing activity at therapeutic dosages. Its elimination half-life after 
intravenous infusion is approximately 9 minutes. Esmolol inhibits the 
beta1 receptors located chiefly in cardiac muscle, but this preferential 
effect is not absolute and at higher doses it begins to inhibit beta2 
receptors located chiefly in the bronchial and vascular musculature. 
Pharmacokinetics and Metabolism 
Esmolol hydrochloride is rapidly metabolized by hydrolysis of the 
ester linkage, chiefly by the esterases in the cytosol of red blood cells and 
not by plasma cholinesterases or red cell membrane acetylchoIinesterase. 
Total body clearance in man was found to be about 20 L/kg/hr, which is 
greater than cardiac output; thus the metabolism of Esmolol is not limited 
by the rate of blood flow to metabolizing tissues such as the liver or 
affected by hepatic or renal blood flow. Esmolol has a rapid distribution 
half-life of about 2 minutes and an elimination half-life of about 9 
minutes. 
Because of its short half-life, blood levels of Esmolol can be 
rapidly altered by increasing or decreasing the infusion rate and rapidly 
eliminated by discontinuing the infusion. 
Consistent with the high rate of blood-based metabolism of 
Esmolol, less than 2% of the drug is excreted unchanged in the urine. 
Within 24 hours of the end of infusion, approximately 73% to 88% of the 
dosage has been accounted for in the urine as the acid metabolite of 
Esmolol. 
Metabolism of Esmolol results in the formation of the 
corresponding free acid and methanol. The acid metabolite has been 
shown in animals to have about 1/1500th the activity of Esmolol and in 
normal volunteers its blood levels do not correspond to the level of beta 
blockade. The acid metabolite has an elimination half-life of about 3.7 
hours and is excreted in the urine with a clearance approximately 
equivalent to the glomerular filtration rate. Excretion of the acid 
metabolite is significantly decreased in patients with renal disease, with 
the elimination half-life increased to about ten-fold that of normals, and 
plasma levels considerably elevated. 
Esmolol has been shown to be 55% bound to human plasma 
protein, while the acid metabolite is only 10% bound. 
PHARMACODYNAMICS 
Clinical pharmacology studies in normal volunteers have 
confirmed the beta blocking activity of Esmolol hydrochloride, showing 
reduction in heart rate at rest and during exercise, and attenuation of 
Isoproterenol-induced increases in heart rate. Blood levels of Esmolol 
have been shown to correlate with extent of beta blockade. After 
termination of infusion, substantial recovery from beta blockade is 
observed in 10 to 20 minutes. 
In human electrophysiology studies, Esmolol produced effects typical of 
a beta blocker; a decrease in the heart rate, increase in sinus cycle length, 
prolongation of the sinus node recovery time, prolongation of the AH 
interval during normal sinus rhythm and during atrial pacing, and an 
increase in antegrade Wenckebach cycle length. 
During exercise, Esmolol produced reductions in heart rate, rate 
pressure product and cardiac index which were also similar to those 
produced by Propranolol, but produced a significantly larger fall in 
systolic blood pressure. 
At thirty minutes after the discontinuation of Esmolol infusion, all 
of the hemodynamic parameters had returned to pre-treatment levels. 
Esmolol produced slightly enhanced bronchomotor sensitivity to 
dry air stimulus. These effects were not clinically significant, and 
Esmolol was well tolerated by asthmatic patients. 
No adverse pulmonary effects were observed in patients with 
COPD who received therapeutic dosages of Esmolol. 
 
Compatibility with Commonly Used Intravenous Fluids 
Esmolol was tested for compatibility with ten commonly used 
intravenous fluids at a final concentration of 10 mg Esmolol 
Hydrochloride per ml. Esmolol was found to be compatible with the 
following solutions and was stable for at least 24 hours at controlled room 
temperature or under refrigeration: 
1. Dextrose (5%) Injection,  
2. Dextrose (5%) in Lactated Ringer's Injection 
3. Dextrose (5%) in Ringer's Injection 
4. Dextrose (5%) and Sodium Chloride (0.45%) Injection,  
5. Dextrose (5%) and Sodium Chloride (0.9%) Injection,  
6. Lactated Ringer's Injection,  
7. Potassium Chloride (40 mEq/liter) in Dextrose (5%) Injection,  
8. Sodium Chloride (0.45%) Injection,  
9. Sodium Chloride (0.9%) Injection,  
10. Esmolol is NOT compatible with Sodium Bicarbonate(5%) 
Injection. 
 
SIDE EFFECTS 
Most adverse effects observed in controlled clinical trial settings 
have been mild and transient. The most important adverse effect has been 
hypotension. 
Cardiovascular 
Symptomatic hypotension (diaphoresis, dizziness) occurred in 12% 
of patients, and therapy was discontinued in about 11%, about half of 
whom were symptomatic. Asymptomatic hypotension occurred in about 
25% of patients. Hypotension resolved during Esmolol infusion in 63% 
of these patients and within 30 minutes after discontinuation of infusion 
in 80% of the remaining patients. Diaphoresis accompanied hypotension 
in 10% of patients. Peripheral ischemia occurred in approximately 1% of 
patients. Pallor, flushing, bradycardia (heart rate less than 50 beats per 
minute), chest pain, syncope, pulmonary edema and heart block have 
each been reported in less than 1% of patients. In two patients without 
supraventricular tachycardia but with serious coronary artery disease 
(post inferior myocardial infarction or unstable angina), severe 
bradycardia/sinus pause/asystole has developed, reversible in both cases 
with discontinuation of treatment. 
 
 
Central Nervous System 
Dizziness has occurred in 3% of patients; somnolence in 3%; 
confusion, headache, and agitation in about 2%; and fatigue in about 1% 
of patients. Paresthesia, asthenia, depression, abnormal thinking, anxiety, 
anorexia, and lightheadedness were reported in less than 1% of patients. 
Seizures were also reported in less than 1% of patients, with one death. 
Respiratory 
Bronchospasm, wheezing, dyspnea, nasal congestion, rhonchi, and 
rales have each been reported in less than 1% of patients. 
Gastrointestinal 
Nausea was reported in 7% of patients. Vomiting has occurred in 
about 1% of patients. Dyspepsia, constipation, dry mouth, and abdominal 
discomfort have each occurred in less than 1% of patients. Taste 
perversion has also been reported. 
Skin (Infusion Site) 
Infusion site reactions including inflammation and induration were 
reported in about 8% of patients. Edema, erythema, skin discoloration, 
burning at the infusion site, thrombophlebitis, and local skin necrosis 
from extravasation have each occurred in less than 1% of patients. 
 
Miscellaneous 
Each of the following has been reported in less than 1% of patients: 
Urinary retention, speech disorder, abnormal vision, midscapular pain, 
rigors, and fever. 
DRUG INTERACTIONS 
1. Catecholamine-depleting drugs, e.g., Reserpine, may have an additive 
effect when given with beta blocking agents. Patients treated 
concurrently with Esmolol and a catecholamine depletor should 
therefore be closely observed for evidence of hypotension or marked 
bradycardia, which may result in vertigo, syncope, or postural 
hypotension. 
2. A study of interaction between Esmolol and Warfarin showed that 
concomitant administration of Esmolol and Warfarin does not alter 
warfarin plasma levels. Esmolol concentrations were equivocally 
higher when given with Warfarin, but this is not likely to be clinically 
important. 
3. When Digoxin and Esmolol were concomitantly administered 
intravenously to normal volunteers, there was a 10-20% increase in 
digoxin blood levels at some time points. Digoxin did not affect 
Esmolol pharmacokinetics.  
4. When intravenous Morphine and Esmolol were concomitantly 
administered in normal subjects, no effect on morphine blood levels 
was seen, but Esmolol steady-state blood levels were increased by 
46% in the presence of morphine. No other pharmacokinetic 
parameters were changed. 
5. The effect of Esmolol on the duration of succinylcholine-induced 
neuromuscular blockade was studied in patients undergoing surgery. 
The onset of neuromuscular blockade by succinylcholine was 
unaffected by Esmolol, but the duration of neuromuscular blockade 
was prolonged from 5 minutes to 8 minutes. 
6. Although the interactions observed in these studies do not appear to be 
of major clinical importance, Esmolol should be titrated with caution 
in patients being treated concurrently with digoxin, morphine, 
succinylcholine or warfarin. 
7. While taking beta blockers, patients with a history of severe 
anaphylactic reaction to a variety of allergens may be more reactive to 
repeated challenge, either accidental, diagnostic, or therapeutic. Such 
patients may be unresponsive to the usual doses of epinephrine used to 
treat allergic reaction. 
8. Caution should be exercised when considering the use of Esmolol and 
Verapamil in patients with depressed myocardial function. Fatal 
cardiac arrests have occurred in patients receiving both drugs. 
Additionally, Esmolol should not be used to control supraventricular 
tachycardia in the presence of agents which are vasoconstrictive and 
inotropic such as dopamine, epinephrine, and norepinephrine because 
of the danger of blocking cardiac contractility when systemic vascular 
resistance is high. 
WARNINGS 
Hypotension 
In clinical trials 20-50% of patients treated with Esmolol have 
experienced hypotension, generally defined as systolic pressure less than 
90 mmHg and/or diastolic pressure less than 50 mmHg. About 12% of 
the patients have been symptomatic (mainly diaphoresis or dizziness). 
Hypotension can occur at any dose but is dose-related so that doses 
beyond 200 mcg/kg/min (0.2 mg/kg/min) are not recommended. Patients 
should be closely monitored, especially if pretreatment blood pressure is 
low. Decrease of dose or termination of infusion reverses hypotension, 
usually within 30 minutes. 
Esmolol should not be used as the treatment for hypertension in 
patients in whom the increased blood pressure is primarily due to the 
vasoconstriction associated with hypothermia. 
Cardiac Failure 
Sympathetic stimulation is necessary in supporting circulatory 
function in congestive heart failure, and beta blockade carries the 
potential hazard of further depressing myocardial contractility and 
precipitating more severe failure. Continued depression of the 
myocardium with beta blocking agents over a period of time can, in some 
cases, lead to cardiac failure. At the first sign or symptom of impending 
cardiac failure, Esmolol should be withdrawn. Although withdrawal may 
be sufficient because of the short elimination half-life of Esmolol, 
specific treatment may also be considered. The use of Esmolol for control 
of ventricular response in patients with supraventricular arrhythmias 
should be undertaken with caution when the patient is compromised 
hemodynamically or is taking other drugs that decrease any or all of the 
following: peripheral resistance, myocardial filling, myocardial 
contractility or electrical impulse propagation in the myocardium. Despite 
the rapid onset and offset of the effects of Esmolol, several cases of death 
have been reported in complex clinical states where Esmolol was 
presumably being used to control ventricular rate. 
Bronchospastic Diseases 
Patients with Bronchospastic diseases should, in general, not 
receive beta blockers. Because of its relative beta1 selectivity and 
titratability, Esmolol may be used with caution in patients with 
bronchospastic diseases. However, since beta1 selectivity is not absolute, 
Esmolol should be carefully titrated to obtain the lowest possible 
effective dose. In the event of bronchospasm, the infusion should be 
terminated immediately; a beta2 stimulating agent may be administered if 
conditions warrant but should be used with particular caution as patients 
already have rapid ventricular rates. 
Diabetes Mellitus and Hypoglycemia 
Esmolol should be used with caution in diabetic patients requiring 
a beta blocking agent. Beta blockers may mask tachycardia occurring 
with hypoglycemia, but other manifestations such as dizziness and 
sweating may not be significantly affected. 
PRECAUTIONS 
1. General: 
Because the acid metabolite of Esmolol is primarily excreted 
unchanged by the kidney, Esmolol should be administered with caution to 
patients with impaired renal function. The elimination half-life of the acid 
metabolite was prolonged ten-fold and the plasma level was considerably 
elevated in patients with end-stage renal disease. 
2. Carcinogenesis, Mutagenesis, Impairment of Fertility: 
Because of its short term usage no carcinogenicity, mutagenicity or 
reproductive performance studies have been conducted with Esmolol. 
3. Pregnancy:  
Teratogenicity studies in rats at intravenous dosages of Esmolol up 
to 3000 mcg/kg/min (3 mg/kg/min) (ten times the maximum human 
maintenance dosage) for 30 minutes daily produced no evidence of 
maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 
10,000 mcg/kg/min (10 mg/kg/min) produced maternal toxicity and 
lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min (1 
mg/kg/min) for 30 minutes daily produced no evidence of maternal 
toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min (2.5 
mg/kg/min) produced minimal maternal toxicity and increased fetal 
resorptions. 
Although there are no adequate and well-controlled studies in 
pregnant women, use of Esmolol in the last trimester of pregnancy or 
during labor or delivery has been reported to cause fetal bradycardia, 
which continued after termination of drug infusion. Esmolol should be 
used during pregnancy only if the potential benefit justifies the potential 
risk to the fetus. 
4. Nursing Mothers 
It is not known whether Esmolol is excreted in human milk; 
however, caution should be exercised when Esmolol is administered to a 
nursing woman. 
5. Pediatric Use 
The safety and effectiveness of Esmolol in pediatric patients have 
not been established. 
OVERDOSE 
Acute Toxicity 
Overdoses of Esmolol can cause cardiac arrest. In addition, 
overdoses can produce bradycardia, hypotension, electromechanical 
dissociation. Cases of massive accidental overdoses of Esmolol have 
occurred due to dilution errors. Use of Esmolol Premixed Injection and 
Esmolol Double Strength Premixed Injection may reduce the potential for 
dilution errors. Some of these overdoses have been fatal while others 
resulted in permanent disability. Bolus doses in the range of 625 mg to 
2.5 g (12.5-50 mg/kg) have been fatal. Patients have recovered 
completely from overdoses as high as 1.75 g given over one minute or 
doses of 7.5 g given over one hour for cardiovascular surgery. The 
patients who survived appear to be those whose circulation could be 
supported until the effects of Esmolol resolved. 
Because of its approximately 9-minute elimination half-life, the 
first step in the management of toxicity should be to discontinue the 
Esmolol infusion. Then, based on the observed clinical effects, the 
following general measures should also be considered. 
Bradycardia: Intravenous administration of atropine. 
Bronchospasm: Intravenous administration of a beta2 stimulating agent 
and/or a theophylline derivative. 
Cardiac Failure: Intravenous administration of a diuretic and/or digitalis 
glycoside. In shock resulting from inadequate cardiac contractility, 
intravenous administration of dopamine, dobutamine, isoproterenol, or 
amrinone may be considered. 
Symptomatic Hypotension: Intravenous administration of fluids and/or 
pressor agents. 
CONTRAINDICATIONS 
Esmolol is contraindicated in patients with sinus bradycardia, heart 
block greater than first degree, cardiogenic shock or overt heart failure  
 
 
 
REVIEW OF LITERATURE 
 
Though laryngoscopy and intubation were done with ease in yester 
years, the anaesthesiologist had to struggle to combat or subdue the 
circulatory or cardiovascular effects of the said procedure in patients with 
compromised circulatory system. Endotracheal intubation cause a reflex 
mediated increase in sympathetic activity in anesthetized patients. 
Enhanced sympathetic activity causes an increase in plasma 
catecholamine concentrations, blood pressure, heart rate, and myocardial 
oxygen demand. 
           King et al (1957)4 used deep Ether anaesthetic to abolish the reflex 
circulatory response to tracheal intubation.  
Ebert TJ et al5 (1989) studied that circulatory response to 
laryngoscopy comparing the effects of Esmolol and Fentanyl and they 
concluded that heart rate response to laryngoscopy was more effectively 
blocked by Fentanyl while Esmolol better retained coronary perfusion 
pressure. There were no complications or ischemic ECG changes in any 
patient. 
  
 
         Ebert TJ and Bernstein JS (1990)6 studied that hemodynamic 
response to Rapid sequence induction and intubation in healthy patients 
with a single bolus dose of Esmolol. They concluded that Esmolol 2 
mg/kg bolus effectively attenuated heart rate, systolic blood pressure, 
diastolic blood pressure, rate pressure product increases produced by 
laryngoscopy and intubation. 
          Sheppard et al7 (1990) compared different bolus dose of Esmolol 
and concluded that attenuation of intubation response is adequate 
following 100 mg of Esmolol.  
  Helfman SM et al9 ( 1991) compared the efficacy of Lidocaine , 
Fentanyl, Esmolol to obtund the intubation responses and concluded that 
only Esmolol provided constant and reliable part against increase in heart 
rate and systolic blood pressure accompanying laryngoscopy and 
intubation. 
             Miller D.R et al (1991)10 in their Canadian multicentre trial 
involving 548 patients concluded that 100 mg bolus Esmolol is safe and 
effective agent. This dose of Esmolol combined with low dose of 
Fentanyl (2-3mcg/kg) results in effective control of both heart rate and 
blood pressure while avoiding important side effect. 
           Vucovic M et al ( 1992)11 concluded randomized control trial with 
500 mcg/kg/min for 2 minutes and maintenance 100 mcg/kg/min till 
intubation and showed that heart rate , systolic blood pressure were 
significantly decreased in Esmolol group. 
Ganbatz C.L et al 11 (1991) also had similar results of Miller D.R et 
al., Parnan S.M et al (1990) also concluded that single bolus dose of 
Esmolol is effective in obtunding intubation response. 
            Vucovic M et al12 (1992) studied about the use of Esmolol for 
management of cardiovascular responses to laryngoscopy and tracheal 
intubation and found that pressor response to laryngoscopy was 
significantly less marked in patients given Esmolol 2 minutes before 
intubation. 
Chung KS et al13 (1992) studied or comparison of Fentanyl, 
Esmolol and their combination for blunting the hyper dynamic responses 
during Rapid sequence intubation and concluded that a combination of 
low dose Fentanyl and Esmolol provides on attenuation to a higher dose 
of Fentanyl for blunting the hyper dynamic response to laryngoscopy and 
intubation. 
             Kovac et al (1992)14 concluded that in an eye patient with 
coronary artery disease, or in any patient whom increase in heart rate may 
be detrimental, Esmolol may be a useful adjunct in combination with low 
dose alfentanil to attenuate the increase in heart rate due to laryngoscopy 
and intubation. 
            Yuan L,Chia YY ( 1994)15 studied the efficiency of bolus dose 
Esmolol in blunting the stress response comparing 100 mg Esmolol 
versus 200 mg Esmolol. They concluded that both bolus dose of Esmolol 
could effectively attenuate the increase the heart rate, hypertension 
produced by laryngoscopy and intubation, furthermore, Esmolol 200 mg 
presented a better hemodynamic stability than100 mg Esmolol. 
Sharma S, Ghania A (1995)16 also concluded adequate 
hemodynamic control was obtained with the administration of Esmolol 
bolus 2mg/kg. 
           Weist. D et al (1995)17 made a review of therapeutic efficacy and 
pharmacokinetic characteristics of Esmolol. 
Singh H et al (1995)18 in their study concluded that Lidocaine 1.5 
mg/kg IV and Nitroglycerine 2 mcg/kg IV were effective in controlling 
the acute hemodynamic response following laryngoscopy and intubation. 
Esmolol 1.4 mg/kg was significantly more effect than either Lidocaine or 
Nitroglycerine in controlling heart rate or mean arterial pressure increase 
during intubation. 
 Sharma et al19 (1996) compared the ability of different bolus doses 
of Esmolol to blunt the hemodynamic response to laryngoscopy and 
intubation in treated hypertensive patients. Concluded that Esmolol 
100mg given as bolus is effective as well as safe in blunting the response. 
Feng C.K et al 20(1996) concluded that Esmolol only could reliably 
offer protection against increase in both heart rate and systolic blood 
pressure. Low dose Fentanyl (2 mcg/kg) prevented heart rate but not 
increase in heart rate and 2 mg/kg lidocaine had no effect. 
Kindler, CH, Schumacher PG21 (1996) studied the hemodynamic 
response to  intubation with  Lidocaine 1.5 mg/kg, Esmolol 1 mg/kg, 
Esmolol 2 mg/kg ,combination of Lidocaine 1.5 mg/kg and  Esmolol 1 
mg/kg and concluded that Esmolol 1-2 mg/kg is reliably effective in 
attenuating the heart rate response to tracheal intubation. Neither of the 
two doses of Esmolol tested nor that of Lidocaine attenuated the blood 
pressure response. Only the combination of Lidocaine and Esmolol 
attenuated the heart rate and blood pressure response to tracheal 
intubation. 
           Wang L et al22 (1999) concluded that 1.2 mg/kg bolus of Esmolol 
is effective and safe. 
           Atlee JL et al23 (2000) compared the efficacy of Esmolol, 
Nicardipine, or their combination to blunt the hemodynamic response 
after intubation and found that the peak increase in blood pressure is 
blunted by a combination of Esmolol and Nicardipine. No single drug or 
combination opposed increase in heart rate. 
             Bensky et al (2000)24 in their study concluded that small dose of 
Esmolol may block the increase in heart rate and blood pressure resulting 
from laryngoscopy and intubation. 
            Figueredo, E.Garcia- Fuentes EM ( 2001)25 compared the results 
of 38 randomized control trial involving different regimen and doses of 
Esmolol and found that the most effective regimen was a loading dose of 
500 mcg/kg/min over 4 minute, followed by continuous infusion dose of 
200-300 mcg/kg/min. 
       Levitt M.A., Dresden GM (2001)26 studied the efficacy of Esmolol 
versus Lidocaine to attenuate the hemodynamic response to intubation in 
isolated head trauma patients and concluded that both have similar 
effects. 
            S. Bansal et al (2002)27 studied the effect of IV Esmolol with or 
without Lidocaine in attenuating hemodynamic response in patients with 
PIH and concluded that Esmolol 1 mg/kg with Lidocaine 1.5 mg/kg is 
effective in attenuating adrenergic response to laryngoscopy and 
intubation. 
            Tan PH et al (2002) 28 made a study on combined use of Esmolol 
and Nicardipine to blunt the hemodynamic response and found that 
patients receiving Esmolol 1mg/kg and Nicardipine 30 mcg/kg showed 
no significant change is systolic blood pressure after tracheal intubation 
compared with baseline. 
Fernandez – Gatinski S et al29 (2004) compared the effects of 
Clonidine, Esmolol, Alfentanil on the level of hypnosis and 
hemodynamic response to laryngoscopy and intubation and concluded 
that none of the study drugs blocked the increase in MAP induced by 
endotracheal intubation but Esmolol provided better overall 
hemodynamic stability. All groups had an adequate level of hypnosis. 
                 
MATERIALS AND METHODS 
 
Sixty ASA I & II patients undergoing elective surgical procedure 
under general anaesthesia with endotracheal intubation were included in 
this study. 
Patients belonging to age group 20-50 years of both the sexes were 
included. 
It is a prospective double blind randomized controlled study. The 
study was approved by the Ethical Committee and were randomly 
grouped into three groups.  
Group A (Esmolol 0.5 mg/kg) = Twenty patients were given Esmolol 
0.5 mg/kg IV 2 minutes before intubation. 
Group B (Esmolol 1.0 mg/kg) = Twenty patients were given Esmolol  
1 mg/kg IV 2 minutes before intubation. 
Group C (Esmolol 1.5 mg/kg) = Twenty patients were given Esmolol 
1.5  mg/kg IV 2 minutes before intubation.  
The surgeon was also duly informed of the study. 
The study was done during the period from May 2009 to August 
2009 in the Department of Anaesthesiology, Chengalpattu Medical 
College, Chengalpattu. 
Inclusion Criteria :   ASA I & II  
            Age 20 – 50 yrs 
            All cases requiring GA 
Exclusion criteria :    Known and difficult airways  
              Esmolol contraindications  
                Not meeting inclusion criteria 
                Patients on beta blockers 
                                   Patients with full stomach 
                                   Patients posted for Emergency surgery 
                                       Hypertension, Diabetes, Ischemic heart disease 
Randomization was done by draw of lots. The follow up of the 
patient and analysis of data were done by personnel blinded to which 
group belonged to.  Drawing of lots for randomization and preparation of 
study was prepared by a consultant who took no further part in the study, 
the rest of the study was conducted by investigator who was blinded to 
the drug injected. 
MATERIALS 
1. Inj.Thiopentone Sodium 2.5% 
2. Inj. Succinylcholine Chloride  
3. Inj. Glycopyrrolate  
4. Inj. Fentanyl citrate 
5. Inj. Esmolol HCl 100mg/10 ml 
6. Disposable 20 ml syringe  
7. Laryngoscope with blades 3 and 4 
8. Endotracheal tubes of varying sizes. 
9. Emergency drugs 
10. Difficult Intubation strategies 
PRE OPERATIVE PREPARATION 
All the patients were admitted and they underwent relevant 
investigations. Preoperatively informed, written consent was obtained 
from the patient. 
Hemogram, Bleeding time, Clotting time 
Blood         –  urea 
                sugar 
Serum  –   creatinine 
                          electrolytes 
X ray Chest 
Electrocardiogram 
Other relevant investigations were obtained on the basis of the 
condition of the patient. 
ANAESTHESIA PROTOCOL 
Pre operative visit was done to allay anxiety and good rapport was 
established with the patient. 
All the patients were given pre operative night sedation with tablet 
Diazepam 10 mg and antacid prophylaxis with tablet Ranitidine 150 mg 
orally. 
INTERVENTION 
Induction of anaesthesia was standardized for all the patients. 
PREMEDICATION 
All the patients were premedicated with Injection. Glycopyrrolate   
4 µg/kg body weight, intra muscularly, 45 minutes before surgery. Basal 
pulse rate and blood pressure were recorded.   
MONITORING 
Non Invasive Automated BP 
Electrocardiogram 
Pulseoximetry 
ETCO2 
Patient shifted to operating table after 45 minutes. In the operating 
room patients were connected to baseline monitors, then intravenous 
access established with 18 gauge cannula and intravenous fluids started. 
Pulse rate, Blood pressure, ECG and SpO2 were recorded. 
PREOXYGENATION 
Preoxygenation was done with 100% oxygen for 3 minutes. 
ADMINISTRATION OF STUDY DRUG 
Inj. Fentanyl 2µg/kg iv given three minute prior to induction.  The 
study drug was taken in a 20 ml syringe and diluted to 20 ml and given as 
bolus over 15-20 seconds two minutes before intubation. One minute 
later anaesthesia was induced with 2.5% Inj. Thiopentone sodium 5mg/kg 
IV. and Inj. Succinyl choline 1.5mg/kg IV given. After satisfying muscle 
relaxation, the patient was intubated with appropriate size endotracheal 
tube after doing a proper laryngoscopy within 10-15 seconds. Conditions 
were prolongation of laryngoscopy time due to difficult intubation, these 
patients were excluded from the study. Endotracheal tube was secured 
after confirming bilateral air entry. Anaesthesia maintained with N2O & 
O2 (66.7%: 33.3%) and IPPV was done. The ETCO2 was maintained at 
the of pressure of 30-35 mmHg.  
The whole intra operative & post operative period were uneventful. 
 
STATISTICAL ANALYSIS 
Heart rate, Systolic blood pressure, Diastolic blood pressure, Mean 
arterial pressure. All recorded data were entered using MS Excel software 
and analysed using STATA software for determining the statistical 
significance. ANOVA test was used to determine the significance among 
three groups. Student’s t test was used to compare the two groups on 
mean values of various parameters. The p-value taken for significance 
is <0.05. 
 
 
 
LIST OF SURGICAL PROCEDURES 
 
S. 
No. 
Surgery Group A Group B Group C 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
Herniorraphy 
Fibroadenoma excision 
Pyelolithotomy  
FESS 
Thyroidectomy 
Appendicectomy 
Screw fixation& Plating 
Gynaecomastia- excision 
Hydrocele  eversion 
Parotidectomy 
Cholecystectomy    
 
5 
4 
3 
3 
2 
1 
2 
 
5 
3 
 
4 
3 
 
2 
1 
1 
1 
5 
3 
1 
2 
2 
1 
1 
 
 
3 
2 
 
   
 
OBSERVATION AND RESULTS 
 
Sixty patients under this study were categorized into three groups. 
They comprised of both sexes with age ranging from 20-50 years. 
 The age, sex and body mass index were equal in all the three 
groups. P value was not significant in the study done (p>0.05). 
DEMOGRPHIC PROFILE 
AGE 
GROUP  20-30 31-40 41-50 TOTAL 
A 9 3 8 20 
B 8 6 6 20 
C 9 4 7 20 
TOTAL 26 13 21 60 
 
SEX 
GROUP  MALE FEMALE TOTAL 
A 8 12 20 
B 10 10 20 
C 9 11 20 
TOTAL 27 33 60 
 
MEAN AGE AND BMI OF PATIENTS BY GROUPS 
AGE 
GROUP  AGE BMI 
A 35.9±8.6 21.5±1.4 
B 35.1±8.7 21.6±1.4 
C 34.9±8.4 22±1.5 
P-value >0.05 >0.05 
 
 
 
BMI 
GROUP  19-24  
>24 
TOTAL 
A 19 1 20 
B 19 1 20 
C 18 2 20 
TOTAL 56 4 60 
 
At intake of study, there is no significance difference on age and 
BMI of patients among the groups. 
The Groups are: 
Group A (Esmolol 0.5 mg/kg):  Twenty patients were given Esmolol 
0.5mg/kg IV 2 minutes before intubation as a bolus. 
Group B (Esmolol 1.0 mg/kg):  Twenty patients were given Esmolol 
1mg/kg IV 2 minutes before intubation as a bolus. 
Group C (Esmolol 1.5 mg/kg):  Twenty patients were given Esmolol 
1.5mg/kg IV 2 minutes before intubation as a bolus. 
Heart rate, systolic blood pressure, diastolic blood pressure and 
mean arterial pressure were measured before premedication, after 
premedication, during administration of the study drug, during induction, 
during intubation, after intubation and following for about 7 minutes after 
laryngoscopy and intubation for every minute. 
 Table I, II, III and IV shows the heart rate, systolic blood pressure, 
diastolic blood pressure and mean arterial pressure comparisons between 
the three groups.   
  
 
HEART RATE 
 
 
TABLE-1 
DISTRIBUTION OF MEAN ± STANDARD DEVIATION OF 
HEART RATE BY GROUPS 
                                  HEART RATE   MEAN±SD VALUES P value 
TIME GROUPS 
A B C 
PRE MED 92.1 ± 8.1[80-110] 90.3 0± 5.2[83-
102] 
90.3±3.4[86-102] >0.05 
ESMOLOL 102.3 ±7.4[92-118] 94.40 ±2.6[91-99] 92.8±3.9[88-101] <0.0001
AT INDUCTION 102.4 ±6.6[94-116] 90.55± 3.8[83-97] 89.4±3.9[84-98] <0.0001
AFTER SCOLINE 98.7± 6.8[90-115] 88.1 ±3.3[80-93] 87.60 ±6.5[77-103] <0.0001
AT INTUBATION 108.7± 6.3[100-124] 96.1 ±3.6[92-102] 92.90 ±6.4[83-108] <0.0001
AT 3 MIN 107.3 ±5.9[100-122] 94.10 ±4.0[85-100] 92.80± 6.4[83-108] <0.0001
AT 4 MIN 105.1±6.0[98-120] 94.10 ±4.2[85-100] 90.8± 6.3[81-105] <0.0001
AT 5 MIN 101 .0±5.9[95-116] 91.55± 4.3[83-98] 89.7± 6.5[80-105] <0.0001
AT 6 MIN 98.9 ±5.9[92-114] 89.85 ±4.3[81-97] 88.6 ± 6.6[78-104] <0.0001
AT 7 MIN 96.6± 5.9[90-111] 88.15  ±4.4[79-96] 87.75 ±6.3[78-103] <0.0001
 
 
 
 
 
 
 
 
 
 
 
SYSTOLIC BLOOD PRESSURE 
 
 
 
TABLE –II 
 
DISTRIBUTION OF MEAN ± STANDARD DEVIATION OF 
SYSTOLIC BLOOD PRESSURE BY GROUPS 
 
SYSTOLIC BLOOD PRESSURE                     MEAN ± SD VALUES P 
VALUE 
TIME GROUPS 
A B C 
PRE MED 122.6 ±6.5[110-132] 124.05± 5.8[110-131] 126.2± 5.7[111-136] >0.05 
ESMOLOL 124.6± 6.26[111-132] 125.65± 6.3[112-135] 123.4 ±6.0[108-134] >0.05 
AT 
INDUCTION 
126.4± 6.6[113-138] 120.95± 5.8[108-129] 122.4 ±6.6[106-130] <0.05 
AFTER 
SCOLINE 
137.8±6.4[125-146] 131.1±5.89[118-140] 130.5 ±6.3[114-138] <0.05 
AT 
INTUBATION 
160.9±7.7[145-171] 150.5± 5.7[138-161] 145.15± 5.3[131-153] <0.0001 
AT 3 MIN 159.2±7.6[148-170] 149.8± 5.3[138-160] 144.6 ±4.9[131-153] <0.0001 
AT 4 MIN 154.1± 6.8[140-166] 145.5± 5.2[135-156] 139.9±4.8[127-148] <0.0001 
AT 5 MIN 148.1±6.5[135-160] 142.2 ± 5.4[132-154] 135.6 ±4.6[123-144] <0.0001 
AT 6 MIN 141.7 ± 6.48[130-152] 136.5± 5.4[128-148] 131.3 ±4.6[119-140] <0.0001 
AT 7 MIN 135.6±6.3[125-146] 131.7± 5.4[123-143] 127.5 ±4.3[117-135] =0.0001 
 
  
DIASTOLIC BLOOD PRESSURE 
 
 
 
TABLE-III 
DISTRIBUTION OF MEAN ± STANDARD DEVIATION OF 
DIASTOLIC BLOOD PRESSURE BY GROUPS 
 
DIASTOLIC BLOOD PRESSURE                    MEAN ± SD VALUES P 
VALUE 
TIME GROUPS 
A B C 
PRE MED 82.3± 5.9[71-90] 82.6 ±5.5[71-90] 84.55 ±6.1[71-92] >0.05 
ESMOLOL 83.7±6.3[72-92] 84 ±5.0[73-92] 82.35 ±5.9[68-90] >0.05 
AT INDUCTION 85.5±6.3[70-96] 80.2± 5.6[68-89] 81.55±5[68-90] <0.05 
AFTER SCOLINE 92.9±5.3[84-101] 86.2 ±4.3[76-96] 87.3±5.1[76-96] <0.0001 
AT INTUBATION 105.1± 5.2[98-116] 98.2 ±4.4[90-106] 95.35±4[88-104] <0.0001 
AT 3 MIN 103.4±4.98[98-113] 97.2 ±4.13[89-104] 95.1±3.6[88-101] <0.0001 
AT 4 MIN 99.6±4.0[93-108] 93.95±4.1[86-101] 91.2± 4.1[81-98] <0.0001 
AT 5 MIN 95.3±4.6[89-104] 90.65± 4.1[82-98] 88.05±3.9[79-95] <0.0001 
AT 6 MIN 91±3.27[86-98] 87.5 ±4.3[80-94] 84.9±3.5[76-90] <0.0001 
AT 7 MIN 87.8±3.7[81-96] 84.4 ±4.1[76-92] 82±3.5[74-88] <0.0001 
 
 
  
 
 
MEAN ARTERIAL PRESSURE 
 
 
 
TABLE-IV 
DISTRIBUTION OF MEAN ± STANDARD DEVIATION OF 
MEAN ARTERIAL PRESSURE BY GROUPS 
MEAN ARTERIAL PRESSURE                                       MEAN±SD VALUES P 
VALUE 
TIME GROUPS 
A B C 
PRE MED 95.3±6.0[84-103] 96.1±5.1[84-103] 98.1±5.3[85-106] >0.05 
ESMOLOL 95.4±6.2[84-102] 98±4.9[86-106] 95.7±5.7[81-103] >0.05 
AT INDUCTION 97.1±6.7[84-110] 94±5.5[84-102] 94.7±5.6[80-103] >0.05 
AFTER SCOLINE 107.1±5.8[96-115] 101.1±4.9[90-110] 101.5±5.0[91-110] <0.05 
AT INTUBATION 123.3±5.8[113-134] 115.4±4.8[106-126] 111.6±4.3[102-120] <0.0001 
AT 3 MIN 121.6± 5.6[115-132] 115.4±4.6[106-125] 111.4±4.4[102-120] <0.0001 
AT 4 MIN 117.4±4.3[110-125] 111.15±4.4[102-119] 107.3±4.7[96-118] <0.0001 
AT 5 MIN 112.8±4.9[106-121] 107.6±4.60[99-118] 103.5±4.0[93-110] <0.0001 
AT 6 MIN 107.5±3.6[101-114] 103.6±4.6[96-112] 99.9±3.7[90-106] <0.0001 
AT 7 MIN 103.6± 4.1[96-112] 100.1±3.7[94-107] 97.1±3.6[88-104] <0.0001 
  
 
 
GROUP A: (Esmolol 0.5mg/kg) 
Heart Rate: 
 The increase in heart rate following laryngoscopy and intubation 
was up to 18%. The rise in heart rate was highest during intubation and 
following intubation and it was high till the sixth minute after intubation. 
It started declining only at the seventh minute. 
 No rhythm disturbances were observed. 
Systolic Blood Pressure: 
 There was up to 31% increase in systolic blood pressure during the 
study period. Highest value attained during intubation and following 
intubation. It started declining only after the study period. 
Diastolic Blood Pressure: 
 Changes in blood pressure were similar to changes in systolic 
blood pressure. There was a 27% rise in diastolic pressure from the 
baseline during the procedure. It was highest during and following 
intubation. It started declining by 10 mmHg at the end of fifth minute. 
Mean Arterial Pressure: 
 The mean arterial pressure rise was up to 29% from the baseline 
during the period of study. It was maximum during and following 
intubation. It started declining by 10 mmHg at the fifth minute. There was 
a further decline of about 8 mmHg at the end of the study.  
Group B (Esmolol 1.0 mg/kg) 
Heart rate: 
The rise in heart rate was about 12% in this group during the whole 
study period. There was a initial decline in heart rate of about 5 per 
minute following Esmolol. The maximum heart rate was observed 
following intubation. It started declining at the fifth minute and there was 
further decline to baseline values at the seventh minute. 
No rhythm disturbances were observed. 
Systolic blood pressure: 
 There was a 24% rise in systolic blood pressure from the baseline 
during the study period. The highest value recorded was during and 
following intubation. It started declining at the end of seventh minute. 
Diastolic blood pressure: 
 Changes in blood pressure were similar to changes in systolic 
blood pressure. There was a 22% rise in diastolic pressure from the 
baseline during the procedure. It was highest during and following 
intubation. It started declining to baseline values at the end of seventh 
minute. 
Mean arterial pressure: 
 There was a 22% rise in mean arterial pressure from the baseline 
during the procedure. It was highest during and following intubation. 
There was a decline in mean arterial pressure at fifth minute.  
Group C (Esmolol 1.5 mg/kg) 
Heart rate: 
There was only about 5% rise in heart rate from the baseline values 
during the entire study period. The maximum rise was observed during 
intubation and at one minute following intubation. The rise was modest of 
about 2-3 beats per minute. It started declining to baseline values at 
fourth minute. There was a further decline in heart rate from the baseline 
values at sixth and seventh minute. 
 No rhythm disturbances were observed. 
Systolic blood pressure: 
 The rise in systolic blood pressure was about 18% during the entire 
study period. The maximum values were observed during intubation. It 
started declining following intubation. At the seventh minute it reached 
the baseline values. 
 
 
Diastolic blood pressure: 
 There was an initial decline in diastolic blood pressure following 
Esmolol and during induction from the baseline. There was a rise of 
about 16% during and following intubation. It started declining at the 
fifth minute and reached baseline value at sixth minute. It further decline 
below baseline at seventh minute.  
Comparison of variables on the three groups 
Variables  Group A Group B Group C 
Heart Rate 18% 12% 5% 
Systolic Blood Pressure 31% 24% 18% 
Diastolic Blood Pressure 27% 22% 17% 
Mean Arterial Pressure 29% 22% 17% 
 
Heart rate and rhythm: 
 In Group A, the rise in heart rate was about 18% from the baseline 
values during and following intubation and it took longer time to reach 
the baseline values. There was a rise of about 16 beats per minute from 
baseline following laryngoscopy and intubation. 
 In Group B, there was an initial fall in heart rate following bolus 
dose of Esmolol and there was a rise of about 8 beats per minute 
following laryngoscopy and intubation. The rise in heart rate was about 
12% from the baseline following laryngoscopy and intubation. It returned 
back to baseline value at the sixth minute. 
  In Group C the rise in heart rate was modest of about 2-3 beats per 
minute and the values returned to baseline values at the fourth minute. 
The rise was 5% from the baseline values with least fluctuation in heart 
rate during the study period. There was a decline in heart rate at fourth 
minute and a further decline was observed at sixth and seventh minute 
from the baseline values. 
 There is no statistical significance among the mean value of  heart 
rate at the pre-medication time(p >0.05). But it is significantly different 
during administration of  Esmolol  bolus, induction, intubation during and 
for about seven minutes following laryngoscopy and intubation. It was 
significantly lower in Group C than in Groups A and B (p<0.001). The 
initial fall in Group B is because of its direct action on cardiac conducting 
system. 
 There was no record of arrhythmias in any of the patients in any of 
the group. This is probably because of all the patients are of ASA Class I 
and II with no history of hypertension or no other cardiac ailments. 
 
Blood Pressure: 
Systolic blood pressure:  
There is no statistical significance on mean value among the three 
groups at Pre-Medication and during administration of Esmolol bolus 
(p>0.05). 
 But, it is statistically significant on all other period of study 
(p<0.001) in between the three groups. 
   There is 31%, 24% and 18% increase from base line during the 
operation in group A, group B and group C respectively. The rise in the 
systolic blood pressure is comparatively less in Group C from the Groups 
A and B. 
Higher mean value reached at intubation in all 3 groups. 
Diastolic blood pressure: 
 There is no statistical significance on mean of Diastolic Blood 
Pressure at Pre-Medication and Esmolol (p>0.05). But, it is statistically 
significant during induction (p<0.05). It is also statistically significant 
from the period of intubation to the end of study period(p<0.001).. 
.  There is up to 27%, 22% and 17% increase from base line during 
the operation in group A , group B and group C respectively. 
Higher mean value reached at intubation in all the groups. 
Mean arterial pressure: 
 There is no statistical significance on mean value of MAP up to 
Induction during the period of study (p>0.05). But it is statistically 
significant after the induction till the end of the study period (p<0.001). 
There is up to 29%, 22% and 17% increase from base line during 
the operation in group A, group B and group C respectively. 
Higher mean value reached at intubation in all 3 groups. 
 
 
                              
DISCUSSION 
 
Laryngoscopy and intubation produces hemo dynamic stress 
response characterized by hypertension and tachycardia. This neuro 
endocrine response causes a variety of complications in patients with 
cardiac disease due to imbalance between myocardial oxygen supply and 
demand like ST changes, ventricular arrhythmias and pulmonary oedema. 
 This is also hazardous in patients with vascular pathologies 
that cause weakening of the lining of the major arteries in particular 
cerebral and aortic aneurysms. In patients with hydrocephalus or intra 
cranial mass lesions the increase in cerebro spinal fluid pressure may 
produce transient impairment of cerebral perfusion.  
Direct laryngoscopy3 that does not exceed 15 seconds duration is 
helpful in minimizing the blood pressure elevation evoked by this painful 
stimulus.  
 In view of the frequent occurrence of hypertension and tachycardia 
during laryngoscopy even in the normotensive individual, it is perhaps 
rather surprising that complications have not been met very often. Reason 
for this may be the transient nature of the hypertension which usually 
lasts for less than ten minutes. It is possible however that some of the 
complications that occur during intubation or even later in the course of 
anaesthesia may be precipitated by an episode of hypertension and 
tachycardia following endo tracheal intubation. 
 This reflex response may be diminished or modified locally, 
centrally or peripherally and attempts have been made to accomplish this 
with varying success by different techniques and agents. No effective 
drug has been found out so far to abolish this response. 
 Ebert TJ and Bernstein JS (1990)6 studied that hemodynamic 
response to Rapid sequence induction and intubation in healthy patients 
with a single bolus dose of Esmolol. They concluded that Esmolol 2 
mg/kg bolus effectively attenuated heart rate, systolic blood pressure, 
diastolic blood pressure increases produced by laryngoscopy and 
intubation. In our study also we took 2 minute as the time for 
administering Esmolol prior to laryngoscopy and intubation. 
 Sheppard et al7 (1990) compared different bolus dose of Esmolol 
and concluded that attenuation of intubation response is adequate 
following 100 mg of Esmolol.  
Helfman SM et al9 ( 1991) compared the efficacy of Lidocaine , 
Fentanyl, Esmolol to obtund the intubation responses and concluded that 
only Esmolol provided constant and reliable part against increase in heart 
rate and systolic blood pressure accompanying laryngoscopy and 
intubation. 
     Miller D.R et al (1991)10 in their Canadian multicentre trial involving 
548 patients concluded that 100 mg bolus Esmolol is safe and effective 
agent. This dose of Esmolol combined with low dose of Fentanyl (2-
3mcg/kg) results in effective control of both heart rate and blood pressure 
while avoiding important side effect. 
Ganbatz C.L et al 11(1991) also had similar results of Miller D.R   
et al.,  
            Vucovic M et al12 (1992) studied about the use of Esmolol for 
management of cardiovascular responses to laryngoscopy and tracheal 
intubation and found that pressor response to laryngoscopy was 
significantly less marked in patients given Esmolol 2 minutes before 
intubation which was similar to our timing of drug administration. 
     Vucovic M et al12 ( 1992) concluded randomized control trial with 
500 mcg/kg/min for 2 minutes and maintenance 100 mcg/kg/min till 
intubation and showed that heart rate , systolic blood pressure were 
significantly decreased in Esmolol group. 
Kovac et al (1992)14 concluded that in an eye patient with coronary 
artery disease, or in any patient whom increase in heart rate may be 
detrimental, Esmolol may be a useful adjunct in combination with low 
dose alfentanil to attenuate the increase in heart rate due to laryngoscopy 
and intubation. 
 Yuan L,Chia YY ( 1994)15 studied the efficiency of bolus dose 
Esmolol in blunting the stress response comparing 100 mg Esmolol 
versus 200 mg Esmolol. They concluded that both bolus dose of Esmolol 
could effectively attenuate the increase the heart rate, hypertension 
produced by laryngoscopy and intubation, furthermore, Esmolol 200 mg 
presented a better hemodynamic stability than100 mg Esmolol. In our 
study Esmolol 1.5 mg/kg provided better hemodynamic control than 
Esmolol 1mg/kg bolus. 
 Sharma S, Ghania A (1995)16 also concluded adequate 
hemodynamic control was obtained with the administration of Esmolol 
bolus 2mg/kg. 
             Weist D et al (1995)17  made a review of therapeutic efficacy and 
pharmacokinetic characteristics of Esmolol. 
 Singh H et al (1995)18 in their study concluded that Lidocaine 1.5 
mg/kg IV and Nitroglycerine 2 mcg/kg IV were effective in controlling 
the acute hemodynamic response following laryngoscopy and intubation. 
Esmolol 1.4 mg/kg was significantly more effect than either Lidocaine or 
Nitroglycerine in controlling heart rate or mean arterial pressure increase 
during intubation. 
Sharma et al19 (1996) compared the ability of different bolus doses 
of Esmolol to blunt the hemodynamic response to laryngoscopy and 
intubation in treated hypertensive patients. Concluded that Esmolol 
100mg given as bolus is effective as well as safe in blunting the response. 
In our study it was Esmolol 1.5 mg/kg IV bolus was effective and safe in 
blunting the response. 
               Feng C.K et al 20(1996) concluded that Esmolol only could 
reliably offer protection against increase in both heart rate and systolic 
blood pressure. Low dose Fentanyl (2 mcg/kg) prevented heart rate but 
not increase in heart rate and 2 mg/kg lidocaine had no effect. 
 Wang L et al22(1999) concluded that 1.2 mg/kg bolus of Esmolol is 
effective and safe. We also used Esmolol in the range of 0.5 mg/kg to 1.5 
mg/kg, which was also safe.  
Bensky et al (2000)24 in their study concluded that small dose of 
Esmolol may block the increase in heart rate and blood pressure resulting 
from laryngoscopy and intubation. 
 Figueredo, E.Garcia- Fuentes EM ( 2001)25 compared the results of 
38 randomized control trial involving different regimen and doses of 
Esmolol and found that the most effective regimen was a loading dose of 
500 mcg/kg/min over 4 minute, followed by continuous infusion dose of 
200-300 mcg/kg/min. 
      Analysis of the length of our study showed that Esmolol 1.5 
mg/kg was more effective in attenuating the heart rate  response to 
laryngoscopy and intubation. 
 Also, Esmolol 1.5 mg/kg was effective in attenuating the blood 
pressure increase accompanying laryngoscopy and intubation. 
CONCLUSION 
  
 On taking into consideration the criteria which I chose to study the 
hemo dynamic changes expected, I found that the dose of Esmolol 1.5 
mg/kg (Group C) to be effective in attenuating the hemo dynamic 
responses during laryngoscopy and endo tracheal intubation with no 
major adverse effects of Esmolol. 
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